53,000+ Patient Study Finds Low-Dose Hydroxychloroquine Associated with Reduced COVID-19 Mortality in China

A multicenter retrospective study led by Wu He and Dao Wen Wang at Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, has found that low doses of hydroxychloroquine (HCQ) were linked to lower mortality rates in hospitalized COVID-19 patients. Published in Frontiers of Medicine, the study analyzed data from 53,030 patients across 138 hospitals in Hubei Province to assess how HCQ dosing influenced clinical outcomes. The results are substantial, raising profound questions as to why this low-cost drug was attacked during the pandemic. Could it be the lower dosage differentiating this study? Other studies have suggested this drug could have reduced morbidity and mortality. The study raises an uncomfortable question: was hydroxychloroquine prematurely discarded due to political and media biases rather than nuanced scientific evaluation?
Tongii Medical College